Epic Sciences Appoints Dr. Greg Critchfield to Board of Directors
13 July 2015
Epic Sciences, Inc. ("Epic Sciences"), a private biotech company that develops diagnostics to personalize the treatment and management of cancer, announced today the appointment of Gregory C. Critchfield, M.D. to Epic Sciences' board of directors. As current chairman, president and CEO of Sera Prognostics, Inc. and former president of Myriad Genetic Laboratories, Inc., Dr. Critchfield has more than 30 years of experience in the clinical pathology and diagnostics space.
10 July 2015
Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced Glenn Noronha, PhD, executive vice president of Research and Development of Clearside, will present at the 2015 International Symposium on Ocular Pharmacology and Therapeutics (ISOPT) Clinical meeting in Berlin, Germany on Friday, July 10. Dr. Noronha’s presentation“Using suprachoroidal administration as an approach to treat noninfectious uveitis – from concept through clinical data” will be part of the afternoon Drug Delivery session.
07 July 2015
Epic Sciences (Epic) announced today an agreement with Laboratory Corporation of America® Holdings (LabCorp®) to provide circulating tumor cell (CTC) technology and support oncology clinical trials in Asia through Covance Drug Development (Covance). Covance will process patient samples in Singapore, and then send samples to Epic's clinical laboratory in San Diego, which has recently been licensed under the Clinical Laboratory Improvement Amendments (CLIA) of 1988, for downstream detection and molecular characterization of CTCs. This agreement expands on a previous contract announced last year between Epic and LabCorp for European clinical trials.
Published Data Support Scientific Basis for Ganaxolone Use in PCDH 19 Female Epilepsy
06 July 2015
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced that Jozef Gecz, Ph.D., Professor of Human Genetics at the Department of Pediatrics, University of Adelaide, published data in the June issue of Human Molecular Genetics, supporting the role for neurosteroids in the pathophysiology of PCDH19 female epilepsy.
06 July 2015
Celtaxsys, Inc., a clinical stage pharmaceutical development company focusing on anti-inflammatory therapeutics, including those with rare and orphan inflammatory disease indications, announced today that it has gained clearance from the U.S. Food and Drug Administration (FDA) to begin a Phase 2 clinical trial of its flagship drug candidate, acebilustat (CTX-4430), in adult CF patients in the US. The regulatory submissions to the health authorities in Europe will be filed soon after.
Research breakthrough to treat girls-only epilepsy
06 July 2015
An international team, led by a University of Adelaide genetics expert, has made a breakthrough discovery which is expected to help thousands of young girls worldwide who are suffering from a rare yet debilitating form of epilepsy.
Celtaxsys $40.00 million Fundraising. William P Reddick Submitted Jun 10 SEC Form
17 June 2015
Celtaxsys, Inc., Corporation just released form D for $40.00 million equity financing. This is a new filing. Celtaxsys was able to sell $21.63 million so far. That is 54.07% of the financing round. The total offering amount was $40.00 million. The fundraising form was filled on 2015-06-10. The reason for the financing was: unspecified. The fundraising still has about $18.37 million more and is not closed yet. We have to wait more to see if the offering will be fully taken.
Clearside Biomedical, Inc. Announces Favorable End-of-Phase 2 Review with the FDA
16 June 2015
Clearside Biomedical, Inc., a biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced a favorable End-of-Phase 2 review with the U.S. Food and Drug Administration (FDA) on its lead drug triamcinolone acetonide (TA) administered via injection into the suprachoroidal space (SCS) for the treatment of macular edema associated with non-infectious uveitis. Agreement was reached with the FDA for the overall development plan with a single pivotal Phase 3 clinical trial, and the company is finalizing plans to initiate this global study.
Tobira Finishes Patient Enrollment for NASH Study
16 June 2015
Tobira Therapeutics, Inc. has finished recruiting patients for its phase 2b CENTAURstudy, which was designed to evaluate a therapy called cenicriviroc (CVC) in patients who suffer from non-alcoholic steatohepatitis (NASH) and liver fibrosis. The company, which is focused on developing and commercializing therapeutic options to treat liver and inflammatory conditions, announced enrollment completion in a press release.
Coda Therapeutics $3.43 million Fundraising. David Pool Published Jun 12 SEC Filing
16 June 2015
Coda Therapeutics Inc, Corporation just submitted form D announcing $3.43 million debt financing. This is a new filing. Coda Therapeutics was able to finance itself with $1.21 million so far. That is 35.16% of the financing offer. The total private financing amount was $3.43 million. The form was filled on 2015-06-12. The reason for the financing was: Total Offering Amount includes estimated amounts receivable by the Issuer upon the exercise of certain warrants to purchase the Issuer’s preferred stock (assuming no net issue exercise, where applicable).
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Four cancer centers opened in Russia in 2023
26 April 2024
Russia and the UAE can simplify the drug registration process
26 April 2024
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024